Eirhub’s Post

🚀 Revolutionizing Biotech & Biopharma with AI in 2024 🧬💡 As we forge ahead in 2024, AI is not just transforming; it's revolutionizing the Biotech and Biopharma landscapes, paving the way for unprecedented breakthroughs in medicine. Companies and research institutions worldwide are harnessing AI's power to catalyze innovations that redefine healthcare. 🔍 Highlights: Insilico Medicine is trailblazing with Pharma.AI, cutting down traditional drug development timelines significantly. Their novel drug candidate for idiopathic pulmonary fibrosis, ISM001, is making waves in Phase I clinical trials. 🌐 Exscientia is redefining rapid drug generation and optimization, partnering with giants like Sanofi to unveil new cancer and immune disease treatments. Their AI-driven approach is a beacon of hope for accelerated preclinical phases. 🧪 BenevolentAI has brilliantly repurposed Baricitinib, unveiling its potential against COVID-19. This pivot underscores AI's prowess in finding new life for existing treatments. 💊 Owkin is at the forefront of personalized medicine, using AI to predict individual treatment responses, ensuring tailored therapeutic strategies that resonate with each patient's unique needs. 🧬 Nference is revolutionizing medical imaging with AI, enabling early disease detection through advanced analysis of MRIs and CT scans, which is crucial for effective treatment. 🖥️ Verily, an Alphabet subsidiary, is optimizing clinical trials with AI, enhancing efficiency and reducing costs, thereby accelerating the journey of new treatments from lab to patients. 📊 These innovators are not just changing the game; they're rewriting the rules, leveraging AI to bring the future of medicine closer than ever. As AI technology evolves, we stand on the brink of more groundbreaking advancements that promise to reshape healthcare as we know it. 🌟 The future is bright, the future is AI-driven, and the future is now. Let's embrace it together! 💡 #Biotech #Biopharma #AIInHealthcare #ODSCEast2024 #InnovationInMedicine #AIRevolution

AI in Pathology Market Size To Hit USD 49 Million by 2028 Download Free Sample Report-https://lnkd.in/dezS7g2A The size of global AI in the pathology market in terms of revenue was estimated to be worth $24 million in 2023 and is poised to reach $49 million by 2028, growing at a CAGR of 15.6% from 2023 to 2028. Companies Working in the Market Philips F. Hoffmann-La Roche Ltd Hologic, Inc. Akoya Biosciences, Inc. Aiforia Technologies Indica Labs OptraSCAN Ibex Medical Analytics Mindpeak GmbH Tribun Health Techcyte Deep Bio Inc. Lumea Visiopharm Aether AI Aiosyn Proscia PathAI Arterys (Acquired by Tempus Labs) konfoong biotech international DoMore Diagnostics verily-life sciences DeepPath 4D Path

It is Friday, which means it is time for #FAQFRIDAY from The Alliance for Artificial Intelligence in Healthcare (AAIH)! Todays question: What are the key healthcare industry categories represented within AAIH? Answer: The AAIH vision is for precision healthcare-- spanning the entire healthcare continuum of biomedical discovery, clinical research and development, and clinical applications-- to foster the delivery of better medicine to patients and populations. Biomedical Discovery: AI-enabled identification of new disease mechanisms, pathways, targets, drugs, diagnostics, and devices by various approaches including imaging and in-silico. Clinical Research: AI-enabled acceleration and facilitation of Phase I-IV clinical trials including patient stratification, enrollment, retention, adherence, and monitoring as well as project management approaches. Medical Diagnostics and Devices: AI approaches that enable image, drug/device, or treatment enhancement; may include diagnostics, wearables and implantable. Precision Medicine: AI-based approaches that enhance patient or population health solutions and care; including diagnostics, genomics, imaging, pathology, patient data, precision and risk analytics. We encourage and anticipate the participation of numerous large pharmaceutical, biotech, diagnostics, and medical devices firms investing in or utilizing AI in their operations as well as the full gamut of tech firms participating in healthcare. #aaih #ai #aiinhealthcare #biomedicaldiscovery #clinicalresearch #medicaldiagnostics #precisionmedicine

Molecular Imaging Meets AI In the dynamic world of pharmaceuticals, Molecular Imaging (MI) paired with Generative AI and Machine Learning (ML) holds promise for transformative advances in diagnostics and drug development. This synergy could reshape our approach to discovering and deploying new therapies. Potential Impacts of MI and AI Integration: Enhanced Drug Discovery: Combining MI with AI might expedite identifying and validating new therapeutic targets, offering a faster path from research to clinical trials. Improved Drug Efficacy Monitoring: The fusion of MI and ML could enable real-time visualization of a drug's effects, potentially refining treatment efficacy assessments and dosing strategies. Personalized Medicine: AI-enhanced MI could lead to more precise personalized treatments by identifying patients most likely to benefit from specific therapies, potentially improving outcomes. Strategic industry shifts towards integrating advanced imaging and AI underscore the potential for more efficient, safe, and tailored drug development. This integration promises to not only streamline the development process but also bring a new level of precision to diagnostics, potentially revolutionizing patient care. #MolecularImaging #GenerativeAI #PrecisionMedicine #PharmaceuticalInnovation

Latest Market Report #AI_in_Pathology Download PDF Brochure-https://lnkd.in/ds7msZxB The global AI in pathology market in terms of revenue was estimated to be worth $24 million in 2023 and is poised to reach $49 million by 2028, growing at a CAGR of 15.6% from 2023 to 2028 The key players functioning in the AI in pathology market include KONINKLIJKE PHILIPS ELECTRONICS NV (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraSCAN (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (딥바이오) Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI 雲象科技 (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath.AI (US), KFBIO and 4D Path Inc (US).

Curious how AI can be used to help speed up the drug development process? Insilico Medicine has provided a great test case that is worth following closely. The NYC-based company’s AI platform, Pharma.AI, identified a ground-breaking drug candidate for idiopathic pulmonary fibrosis in just 18 months, a process that traditionally takes six years and over $400 million. By leveraging deep learning at every step, from target identification to predicting clinical trial outcomes, they've accelerated the drug discovery process exponentially. Now, their first AI-driven candidate has entered Phase 2 trials, marking a major milestone in the field of AI-accelerated drug development. The Phase II study is expected to take several months, and we are eager to hear about the results, and to see what other companies can use AI to speed up the drug development process. We love working with cutting edge companies like these who intrinsically understand the value technology can bring to clinical trial efficiency. Let's talk! #AI #DrugDiscovery #ClinicalTrials #TheFutureisHere

Our portfolio company, Ultromics, exemplifies how success in AI diagnostics depends on staying ahead of the curve and being agile enough to pivot as regulation evolves. Their journey, from initial conversations about the potential of AI to securing multiple #FDA clearances and breakthrough designations, underscores the importance of foresight, adaptability, and close collaboration with regulatory bodies. Ultromics' approach to product development thoughtfully incorporated considerations around evolving FDA regulations. The company navigated these changes by proactively engaging with the Agency, which allowed them to not only comply with current standards but also anticipate future shifts, facilitating the rapid development and approval of their AI-based echocardiography solutions—to be exact, four FDA clearances and two FDA Breakthrough Designations in four years. The shift in the FDA’s regulatory pathway for class II devices, combined with advancements in AI-driven diagnostics, opens up new possibilities for early and accurate diagnosis of conditions that were previously challenging to identify. Ultromics’ strategic partnerships and development of a comprehensive ecosystem of technologies for cardiac amyloidosis screening indicate a broader trend toward more integrated, AI-enhanced diagnostic solutions in healthcare. This is a case study in the making that the industry should be following closely, and more universities known for their prolific transfer of healthcare technology, like the University of Oxford where Ultromics was born, should add to their curricula. Read more here in a blog post penned by Ross Upton, PhD, the company's founder and CEO. https://lnkd.in/d2B5pdBF Nina Capital #wearenina #AI

#AI in the Clinic: Supporting #Drug Development AI's ability to interpret data and learn from it is transforming how we approach #research and innovation in the Life Sciences industry. It is revolutionizing drug discovery, making it more efficient and cost-effective. One key area where AI shines is in the optimization of clinical trials. By leveraging advanced imaging and AI-driven biomarkers, we can identify treatment efficacy earlier and with greater precision. This not only accelerates the development process but also enhances #patient outcomes. At IAG, IMAGE ANALYSIS GROUP, we're passionate about harnessing the power of AI to drive meaningful advancements in #healthcare. With our expertise in AI-driven methodologies and innovative imaging technologies, we're proud to partner with biotech and pharma companies to unlock the full potential of AI in drug development. Ready to embark on your AI initiative? Reach out to our expert team at IAG to explore how AI can supercharge your drug development efforts and bring life-saving treatments to market faster. #AIinHealthcare #Machinelearning #DrugDevelopment #Innovation #ArtificialIntelligence #lifesciences #biotechnologyindustry #clinicaltrials

Please check out our latest blog on Digital Biomarkers. Excelra Sherin Ann Eapen Dr. Manti Kumar Saha, PhD Dr. Debamitra Chakravorty

𝗔𝗜 𝗨𝗻𝘃𝗲𝗶𝗹𝘀 𝗡𝗼𝘃𝗲𝗹 𝗪𝗲𝗮𝗽𝗼𝗻 𝗔𝗴𝗮𝗶𝗻𝘀𝘁 𝗠𝗥𝗦𝗔 In a study published in Nature, researchers from Integrated Biosciences, Inc. and Massachusetts Institute of Technology have leveraged "explainable" AI to unlock a new class of antibiotics with potent activity against methicillin-resistant Staphylococcus aureus (MRSA). This breakthrough could mark a critical step forward in combating the global threat of antibiotic resistance. The trained models tackled a vast chemical space of 12 million compounds efficiently filtering them to identify 283 candidates with high anti-MRSA potential. This approach significantly reduces the workload compared to traditional trial-and-error methods. 𝗘𝘅𝗽𝗹𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗠𝗼𝗱𝗲𝗹𝘀 ➡ By leveraging Chemprop and Monte Carlo tree search, the researchers built neural networks that not only predict anti-MRSA activity but also decipher the underlying chemical rationale. This transparent approach unveils promising structural motifs for future drug design. 𝗡𝗼𝘃𝗲𝗹 𝗠𝗢𝗔 ➡The lead candidates exhibit a novel mode of action, disrupting bacterial membranes without targeting proteins. This mechanism is less prone to resistance development, a major advantage in the battle against evolving superbugs. 𝗜𝗻 𝗩𝗶𝘃𝗼 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆  ➡Both topical and systemic administration in mouse models demonstrated significant reductions in MRSA burden, even in advanced infections with signs of sepsis.    This work represents the first discovery of a new antibiotic class in decades, offering a powerful tool to combat escalating antibiotic resistance. Researchers plan to advance the promising candidates towards clinical trials, collaborating with NFP Phare Bio to bring these life-saving drugs to patients.   This study exemplifies the transformative potential of AI in healthcare. By unlocking the secrets of drug-bacteria interactions, it is hoped that explainable AI models will propel us toward a future where we can effectively combat even the most formidable superbugs. #AntibioticResistance #AIinDrugDiscovery #MRSA #Biotech #DrugDiscovery #FutureofMedicine